Skip to main content

Table 4 Descriptive analysis of antineoplastic dose errors

From: Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costs

  Underdosage Overdosage   
Percentage of error1 < 10 [10-50[ [50-100] > 100 < 10 [10-50[ [50-100] > 100 Total Frequency of drug prescriptions (%)
Bevacizumab - - 2 - 1 - - - 3 0.65
Bleomycin - - - - - 3 - - 3 3.1
Bortezomib 1 - - - - 3 1 - 5 3.36
Carboplatin 4 9 1 - 5 14 2 - 35 2.66
Cetuximab - - - - - - 2 - 2 0.99
Cisplatin - - - - - 2 1 3 6 5.22
Cyclophosphamide 1 2 1 - 1 2 1 - 8 6.31
Cytarabine - 1 - - - - - - 1 3.23
Dacarbazine - - - - - 1 - - 1 1.71
Docetaxel - - - - - 2 - 1 3 2.69
Doxorubicin - - 1 - 2 - - 1 4 8.04
Drug in clinical trial - - 1 - - 1 - - 2 0.5
Liposomal doxorubicin - - - - - 2 - - 2 0.31
Epirubicin - - 1 - - - - - 1 0.6
Etoposide 1 1 - - 1 1 - 1 5 7.82
Fluorouracil 4 - 1 - 4 9 1 - 19 12.1
Gemcitabine - 1 - - - 5 3 1 10 4.91
Ifosfamide - 2 2 - 2 2 - - 8 2.67
Irinotecan 1 - - - 1 1 - 1 4 2.57
Methotrexate - - 1 - - 1 - - 2 1.6
Oxaliplatin 1 2 - - 1 7 1 1 13 2.15
Paclitaxel 1 - - - - 3 - - 4 1.63
Raltitrexed - - - - - - 1 - 1 0.1
Rituximab - 2 - - 4 - 1 - 7 8.21
Trastuzumab - 1 1 - - - - - 2 1.78
Vinblastine - - - - 1 1 - 1 3 2.01
Vincristine - - - - 1 4 3 - 8 5.18
Vindesine - - - - 1 - - - 1 0.75
Vinorelbine - - - - - 2 1 1 4 2.12
Total 14 21 12 - 25 66 18 11 167  
  1. 1 Percentage of error = (theoretical dose - incorrect dose)/theoretical dose *100